Predicting early blast transformation in chronic-phase chronic myeloid leukemia: Is immunophenotyping the missing link?

Cancer

Volumn 121, Issue 6, 2015, Pages 872-875

  El Rassi, Fuad ^a   Bergsagel, John D ^a   Arellano, Martha ^a   Gaddh, Manila ^a   Jillella, Anand ^a   Kota, Vamsi ^a   Heffner, Leonard T ^a   Winton, Elliott F ^a   Khoury, Hanna Jean ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Chronic myeloid leukemia (CML); Chronic phase; Early blast phase; Flow cytometry

Indexed keywords

BOSUTINIB; DASATINIB; IMATINIB; NILOTINIB; PONATINIB;

ADULT; ALLOGENEIC STEM CELL TRANSPLANTATION; ARTICLE; BLAST TRANSFORMATION; CANCER GROWTH; CHILD; CHRONIC MYELOID LEUKEMIA; CHRONIC PHASE CHRONIC MYELOID LEUKEMIA; CONTROLLED STUDY; DRUG RESPONSE; FLOW CYTOMETRY; HUMAN; IMMUNOPHENOTYPING; LEUKEMIA REMISSION; MAJOR CLINICAL STUDY; PREDICTION; PREDICTIVE VALUE; PRIORITY JOURNAL; BLAST CELL CRISIS; FEMALE; IMMUNOLOGY; MALE; MYELOID LEUKEMIA; PATHOLOGY; PROCEDURES;

ADULT; BLAST CRISIS; CHILD; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOPHENOTYPING; LEUKEMIA, MYELOID, CHRONIC-PHASE; MALE; PREDICTIVE VALUE OF TESTS;

EID: 84924145944     PISSN: 0008543X     EISSN: 10970142     Source Type: Journal    
DOI: 10.1002/cncr.29142     Document Type: Article

References (18)

1. Vardiman JW, Harris NL, Brunning RD. The World Health Organization (WHO) classification of the myeloid neoplasms. Blood. 2002;100:2292-2302.
2. Weir EG, Borowitz MJ. Flow cytometry in the diagnosis of acute leukemia. Semin Hematol. 2001;38:124-138.
3. Wood BL, Arroz M, Barnett D, et al. 2006 Bethesda International Consensus recommendations on the immunophenotypic analysis of hematolymphoid neoplasia by flow cytometry: optimal reagents and reporting for the flow cytometric diagnosis of hematopoietic neoplasia. Cytometry B Clin Cytom. 2007;72(suppl 1): S14-S22.
4. Kussick SJ, Wood BL. Four-color flow cytometry identifies virtually all cytogenetically abnormal bone marrow samples in the workup of non-CML myeloproliferative disorders. Am J Clin Pathol. 2003;120: 854-865.
5. Kussick SJ, Wood BL. Using 4-color flow cytometry to identify abnormal myeloid populations. Arch Pathol Lab Med. 2003;127: 1140-1147.
6. Ligler FS, Brodsky I, Schlam ML, Fuscaldo KE. Cytogenetics and flow cytometry may predict phenotype of CML blast crisis. Cancer Detect Prev. 1985;8:317-323.
7. Ligler FS, Brodsky I, Schlam ML, Fuscaldo KE. Cytogenetics and cell surface marker analysis in CML-1. Prediction of phenotype of acute phase transformation. Leuk Res. 1985;9:1093-1098.
8. Cruse JM, Lewis RE, Pierce S, Lam J, Tadros Y. Aberrant expression of CD7, CD56, and CD79a antigens in acute myeloid leukemias. Exp Mol Pathol. 2005;79:39-41.
9. O'Brien SG, Guilhot F, Larson RA, et al. Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronicphase chronic myeloid leukemia. N Engl J Med. 2003;348:994-1004.
10. Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2010;362:2260-2270.
11. Saglio G, Kim DW, Issaragrisil S, et al. Nilotinib versus imatinib for newly diagnosed chronic myeloid leukemia. N Engl J Med. 2010; 362:2251-2259.
12. Cortes JE, Kim DW, Kantarjian HM, et al. Bosutinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia: results from the BELA trial. J Clin Oncol. 2012;30:3486-3492.
13. Preudhomme C, Guilhot J, Nicolini FE, et al. Imatinib plus peginterferon alfa-2a in chronic myeloid leukemia. N Engl J Med. 2010; 363:2511-2521.
14. de Lavallade H, Apperley JF, Khorashad JS, et al. Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol. 2008; 26:3358-3363.
15. Berger U, Engelich G, Reiter A, Hochhaus A, Hehlmann R. Imatinib and beyond-the new CML study IV. A randomized controlled comparison of imatinib vs imatinib/interferon-alpha vs imatinib/lowdose AraC vs imatinib after interferon-alpha failure in newly diagnosed chronic phase chronic myeloid leukemia. Ann Hematol. 2004; 83:258-264.
16. Sokal JE, Cox EB, Baccarani M, et al. Prognostic discrimination in "good-risk" chronic granulocytic leukemia. Blood. 1984;63:789-799.
17. Hasford J, Baccarani M, Hoffmann V, et al. Predicting complete cytogenetic response and subsequent progression-free survival in 2060 patients with CML on imatinib treatment: the EUTOS score. Blood. 2011;118:686-692.
18. Khoury HJ, Kukreja M, Goldman JM, et al. Prognostic factors for outcomes in allogeneic transplantation for CML in the imatinib era: a CIBMTR analysis. Bone Marrow Transplant. 2012;47: 810-816.